| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/05/2002 | WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 12/05/2002 | WO2002059150A3 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 12/05/2002 | WO2002059146A3 Peptides having affinity for the gp120 viral protein and use thereof |
| 12/05/2002 | WO2002059116A3 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 12/05/2002 | WO2002056902A3 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 12/05/2002 | WO2002047728A3 Treatment of posterior capsule opacification |
| 12/05/2002 | WO2002042321A3 Mixed fibrils |
| 12/05/2002 | WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 12/05/2002 | WO2002020766A3 G-csf analog compositions and methods |
| 12/05/2002 | WO2002016413A3 Cripto tumour polypeptide |
| 12/05/2002 | WO2002006453A3 Regulation of human desc1-like serine protease |
| 12/05/2002 | WO2001093909A3 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 12/05/2002 | WO2001093840A2 Ligands of integrin receptors |
| 12/05/2002 | WO2001079448A3 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 12/05/2002 | WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| 12/05/2002 | WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 12/05/2002 | WO2001032685A9 Gene expression directed by a super-psa promoter |
| 12/05/2002 | WO2001029269A3 Gene expression profiling of inflammatory bowel disease |
| 12/05/2002 | US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 12/05/2002 | US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 12/05/2002 | US20020183515 Asymmetric synthesis of a key intermediate for making benazepril and analogues thereof |
| 12/05/2002 | US20020183513 Tricyclic alkylhydroxamate derivatives |
| 12/05/2002 | US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same |
| 12/05/2002 | US20020183399 Method and compositions for treating rosacea |
| 12/05/2002 | US20020183396 Local anesthetic methods and kits |
| 12/05/2002 | US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders |
| 12/05/2002 | US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B) |
| 12/05/2002 | US20020183379 Kits for determining risk of Alzheimer's disease |
| 12/05/2002 | US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis |
| 12/05/2002 | US20020183368 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 12/05/2002 | US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| 12/05/2002 | US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond |
| 12/05/2002 | US20020183362 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation |
| 12/05/2002 | US20020183361 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 12/05/2002 | US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels |
| 12/05/2002 | US20020183357 Therapy of stress urinary incontinence by administering a compound that is an alpha 1A adrenoceptor agonist and an alpha 1B antagonist |
| 12/05/2002 | US20020183356 Local anesthetic methods and kits |
| 12/05/2002 | US20020183351 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse |
| 12/05/2002 | US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea |
| 12/05/2002 | US20020183339 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
| 12/05/2002 | US20020183338 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 12/05/2002 | US20020183335 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| 12/05/2002 | US20020183334 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder |
| 12/05/2002 | US20020183329 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline |
| 12/05/2002 | US20020183327 For use as analgesics |
| 12/05/2002 | US20020183324 Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| 12/05/2002 | US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy |
| 12/05/2002 | US20020183321 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 12/05/2002 | US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer |
| 12/05/2002 | US20020183318 Novel derivatives of flavones, xanthones and coumarins |
| 12/05/2002 | US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers |
| 12/05/2002 | US20020183312 Combination of cyamemazine and an atypical neuroleptic |
| 12/05/2002 | US20020183311 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists |
| 12/05/2002 | US20020183306 Combination treatment for sleep disorders including sleep apnea |
| 12/05/2002 | US20020183305 For therapy of hyperlipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals |
| 12/05/2002 | US20020183303 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive- compulsive disorder, post-traumatic stress disorder, sexual dysfunction |
| 12/05/2002 | US20020183293 Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage |
| 12/05/2002 | US20020183291 Use of an aromatase inhibitor selected from exemestane, anastrozole, letrozole and fadrozole in the preparation of a medicament for use in treating gynecomastia in a patient undergoing treatment with antiandrogen |
| 12/05/2002 | US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels |
| 12/05/2002 | US20020183283 Meiosis regulating compounds |
| 12/05/2002 | US20020183282 For skin, muscle, ocular or gastric mucosal healing |
| 12/05/2002 | US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient |
| 12/05/2002 | US20020183266 Combination comprising combretastatin and anticancer agents |
| 12/05/2002 | US20020183264 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same |
| 12/05/2002 | US20020183261 Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone; can be useful for improvement of osteoporosis, bone fracture, bone pain, etc |
| 12/05/2002 | US20020183260 For therapy of cardiovascular disorders in mammals; for inhibiting both angiotensin converting enzyme and neutral endopeptidase in mammals |
| 12/05/2002 | US20020183259 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 12/05/2002 | US20020183256 Cytostatic-integrin conjugates having specifically cleavable linking units |
| 12/05/2002 | US20020183253 Effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with ocular neovascularization to an ocular neovascularization inhibiting effective amount |
| 12/05/2002 | US20020183248 Locally administering to a cutaneous site at least one lectin capable of interfering with the infective capability of a pathogenic microorganism toward dermal tissue, in an amount effective to diminish infective capability microorganism |
| 12/05/2002 | US20020183242 Peptide antiangiogenic drugs |
| 12/05/2002 | US20020183237 Methods of performing vagal-induced asystole |
| 12/05/2002 | US20020182683 Vascular endothelial growth factor 2 |
| 12/05/2002 | US20020182650 Inhibitors of binding between proteins and macromolecular ligands |
| 12/05/2002 | US20020182276 Morinda citrifolia (Noni) enhanced animal food product |
| 12/05/2002 | US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 12/05/2002 | US20020182268 Plant extracts, especially for breast cancer |
| 12/05/2002 | US20020182265 Lubricious coatings for substrates |
| 12/05/2002 | US20020182255 Especially a sustained release composition for the treatment of ocular and periocular infections. |
| 12/05/2002 | US20020182219 Cancer immunotherapy |
| 12/05/2002 | US20020182208 Glycosylated antibody |
| 12/05/2002 | US20020182204 Combination of a taxane and a cyclin-dependent kinase |
| 12/05/2002 | US20020182198 Purified MANF polypeptide (mature astrocyte-derived neurotrophic factor) of given sequence |
| 12/05/2002 | US20020182192 Administering bone marrow cells to the mammal, such as allogeneic cells or autologous cells engineered to express dystrophin or other gene products |
| 12/05/2002 | US20020182185 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/05/2002 | US20020182156 Contacting the melanocyte with a melanin synthesis inhibiting amount of a fatty acid synthase (FAS) inhibitor (such as cerulenin) to reduce melanin synthesis in the melanocyte |
| 12/05/2002 | DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases |
| 12/05/2002 | DE10125901A1 Kombination von Liponsäuren, Carnitinen und Kreatinen in Lebens- und Arzneimitteln Combination of lipoic acids, carnitines and creatines in food and medicines |
| 12/05/2002 | DE10124820A1 Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut Composition and use of substances for the stabilization of sulfur-containing amino acids in blood |
| 12/05/2002 | CA2487014A1 A method of improving the growth performance of an animal |
| 12/05/2002 | CA2452154A1 Carbohydrate modifying agent and drinks containing the modifying agent |
| 12/05/2002 | CA2449245A1 Small molecule antagonists of bcl2 family proteins |
| 12/05/2002 | CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 12/05/2002 | CA2449019A1 Method for treating nerve injury caused by surgery |
| 12/05/2002 | CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449000A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 12/05/2002 | CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins |
| 12/05/2002 | CA2448894A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 12/05/2002 | CA2448643A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug |